Prof. Mikhail Blagosklonny is a teaching and research professor at revered Roswell Park Cancer Institute, Buffalo. To this end, he has undertaken several extensive research projects on hematology, possible ways of life extension, clinical trials, medicine, and oncology. Mikhail is respected in his field for his relentless efforts and commitment to every research project he puts his hands on. Earlier in his professional career, Prof. Blagosklonny was a lecturer at New York Medical College. Before landing his current job, Mikhail was among the senior most research professionals at Ordway Research Institute.
Mikhail’s Academic Background
Mikhail Blagosklonny’s academic journey is nothing short of impressive. Having grown up in Russia, he started his long and prosperous medical career by pursuing a medical program at the Pavlov State Medical University situated in St. Petersburg. He later went back to the same prestigious institution and narrowed down to internal medicine for his master’s degree. Mikhail’s undying thirst for knowledge took him back to the same University for a Ph.D. degree where he based his doctoral research in experimental medicine and cardiology.
Mikhail’s Career Path
Mikhail Blagosklonny arrived in the United States in 2002 equipped with his splendid academic papers. The first institution to take note of the young scholar’s brilliance was the New York Medical College that immediately hired him as an associate professor of medicine. Around the same time, the Ordway Research Institute appointed Mikhail to be a senior scientist at the institution. He left this position in 2009 for his current job. Check Mikhail’s profile in LinkedIn
Mikhail’s pan-mTOR Hypothesis
Mikhail Blagosklonny recently collaborated with his colleague researcher at Roswell Park Cancer Institute, Olga V Leontieva, in a research project that they named as Gerosuppression by pan-mTOR inhibitors. An article on the subject that appeared in the Aging journal in December last year had a total of 113 references and more than 2000 citations. Their research hypothesis was that the same way rapamycin slows down the aging process in living organisms, pan-mTOR inhibitors are likely to have the same effect since rapamycin largely borrows from mTOR. In the research, the two professors put their focus on Gerosuppressive concentrations levels in pan-mTOR inhibitors. At the end of the research, they submitted that pan-mTOR inhibitors have the potential of extending life but cautioned that their anti-aging dosage must be lower than the anti-cancer dosage.